The deadline to respond to EMA Art. 5(3) Referral on NITROSAMINES is fast approaching. MAHs are obliged to submit the conclusions of risk evaluations for all of their medicinal products containing chemically synthesized API by 26.03.2020.
Kinapse can provide support for each step of the process, including:
Use the button below to download the PDF and learn more.